A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Evan Hersh, MD
University of Arizona
Principal Investigator - Ileana Elias, MD
Celgene Corporation
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
112 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Port Macquarie Base Hospital
Port Macquarie, New South Wales, Australia
- Royal North Shore Hospital
Sydney, New South Wales, Australia
- Sydney West Cancer Trials Centre/westmead Hospital
Westmead, New South Wales, Australia
- Royal Adelaide Hospital, Department of Medical Oncology
Adelaide, South Australia, Australia
- Royal Hobart Hospital
Hobart, Tasmania, Australia
- Alfred Hospital
Melbourne, Victoria, Australia
- Sir Charles Gairdner Hospital
Nedlands Perth, Western Australia, Australia
- Royal Perth Hospital
Perth, Western Australia, Australia
- Tom Baker Cancer Centre
Calgary, Alberta, Canada
- Cross Cancer Institute
Edmonton, Alberta, Canada
- Bcca Centre for the Southern Interior
Kelowna, British Columbia, Canada
- Bcca, Centre for the Southern Interior
Kelowna, British Columbia, Canada
- Bc Cancer Agency-Fraser Valley Ctr.
Surrey, British Columbia, Canada
- Bc Cancer Agency-Vancouver
Vancouver, British Columbia, Canada
- Bc Cancer Agency-Vancouver Island Ctr.
Victoria, British Columbia, Canada
- London Regional Cancer Program
London, Ontario, Canada
- Credit Valley Hospital
Missiauga, Ontario, Canada
- the Ottawa Hospital Regional Cancer Centre
Ottawa, Ontario, Canada
- Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
- Mcgill University Dept. of Oncology Clinical Research Program
Montreal, Quebec, Canada
- Hopital Saint Andre' Chu de Bordeaux
Bordeaux, France
- Centre Hospitaller Universitaire de Grenoble
Grenoble, France
- Chru Hopital Claude Huriez
Lile Cedax, France
- Hopital Dypuytren-Chu de Limoges
Limoges, France
- Centre Leon Berad
Lyon, France
- Hopital Sainte Marguerite
Marseille, France
- Chu Hopital Saint Eloi
Montepellier Cedex 5, France
- Centre Regional Val D' Aurelle Paul Lamarque
Montpellier, France
- Hopital de 1 Archet 2
Nice, France
- Groupe Hospitalier Cochin-St. Vincent de Paul
Paris, France
- Hopital Bichat
Paris, France
- Hopital Saint-Louis
Paris, France
- Institut Gustave Roussy (igr) Centre de Lutte Contre Le Canc
Villejuif, France
- Universitaetsklinkum Heidelberg
Heidelber, Baden-Wurttemberg, Germany
- Universitaetsklinkum Heidelberg
Heidelberg, Baden-Wurttemberg, Germany
- Universitaetsklinkum Tuebingen
Tübingen, Baden-Wurttemberg, Germany
- Universitaetsklinkum Wuerzburg Ps
Würzburg, Bavaria, Germany
- Universitaetsklinkum Hamburg-Eppendorf
Hamburg, Free and Hanseatic City of Hamburg, Germany
- Univeritaetsklinkum Goettingen
Gottington, Lower Saxony, Germany
- Medizinische Hochschuke Hannover
Hanover, Lower Saxony, Germany
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 23 Apr 2009
- Primary completion
- 1 Jun 2012
- Completion
- 12 Feb 2014
- Last update posted
- 30 Oct 2019
- Registered enrollment
- 529
- Registry id
- NCT00864253
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.